BeOne Medicines Ltd.ONCEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Revenue
$751.7M
Gross Profit
$626.7M
Operating Profit
$-261.3M
Net Profit
$-251.2M
Gross Margin
83.4%
Operating Margin
-34.8%
Net Margin
-33.4%
YoY Growth
67.9%
EPS
$-0.19
BeOne Medicines Ltd. Q1 FY2024 Financial Summary
BeOne Medicines Ltd. reported revenue of $751.7M (up 67.9% YoY) for Q1 FY2024, with a net profit of $-251.2M (up 27.9% YoY) (-33.4% margin). Cost of goods sold was $124.9M, operating expenses totaled $888.1M.
Key Financial Metrics
| Total Revenue | $751.7M |
|---|---|
| Net Profit | $-251.2M |
| Gross Margin | 83.4% |
| Operating Margin | -34.8% |
| Report Period | Q1 FY2024 |
BeOne Medicines Ltd. Annual Revenue by Year
BeOne Medicines Ltd. annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $5.3B |
| 2024 | $3.8B |
| 2023 | $2.5B |
| 2022 | $1.4B |
BeOne Medicines Ltd. Quarterly Revenue & Net Profit History
BeOne Medicines Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.5B | +32.8% | $66.5M | 4.4% |
| Q3 FY2025 | $1.4B | +41.0% | $124.8M | 8.8% |
| Q2 FY2025 | $1.3B | +41.6% | $94.3M | 7.2% |
| Q1 FY2025 | $1.1B | +48.6% | $1.3M | 0.1% |
| Q4 FY2024 | $1.1B | +77.8% | $-151.9M | -13.5% |
| Q3 FY2024 | $1.0B | +28.2% | $-121.3M | -12.1% |
| Q2 FY2024 | $929.2M | +56.1% | $-120.4M | -13.0% |
| Q1 FY2024 | $751.7M | +67.9% | $-251.2M | -33.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $751.7M | $929.2M | $1.00B | $1.13B | $1.12B | $1.32B | $1.41B | $1.50B |
| YoY Growth | 67.9% | 56.1% | 28.2% | 77.8% | 48.6% | 41.6% | 41.0% | 32.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $5.67B | $5.71B | $5.83B | $5.92B | $5.84B | $6.30B | $7.63B | $8.19B |
| Liabilities | $2.31B | $2.35B | $2.39B | $2.59B | $2.34B | $2.53B | $3.50B | $3.83B |
| Equity | $3.36B | $3.37B | $3.44B | $3.33B | $3.50B | $3.77B | $4.13B | $4.36B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-308.6M | $-95.6M | $188.4M | $75.2M | $44.1M | $263.6M | $402.6M | $417.3M |